NIH Grants Archives

SBIR Contract Topic 125 - Development of Long-Acting Treatments for HCV Cure

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the high-risk research needed to develop new and innovative sustained release antiviral strategies for treatment of HIV disease or the prevention of HIV transmission and acquisition. Adherence to dosing regimens is a shared critical issue for both HIV treatment and prevention.

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate development of safe and effective long-acting drug delivery systems (LA-DDS) for improved, simplified treatment of HIV-1 in children. This FOA invites applicants engaged in the development of existing LA-DDS platforms at early product development stages to perform specific preclinical activities that enable product optimization and accelerated translation to HIV-1 infected children. Collaborative research partnerships with industry are required.

Application Deadline: March 13, 2019 - 5:00 PM local time of applicant

Non-adherence to anti-retroviral therapy by HIV+ patients results in increased viral loads and risk of emergence of drug-resistant HIV strains. This poses a major public health threat. Lyndra Co. has developed an orally available, long-acting drug delivery system that it will now formulate to deliver anti-retrovirals.